204 related articles for article (PubMed ID: 22748449)
1. Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer.
Haigentz M; Kim M; Sarta C; Lin J; Keresztes RS; Culliney B; Gaba AG; Smith RV; Shapiro GI; Chirieac LR; Mariadason JM; Belbin TJ; Greally JM; Wright JJ; Haddad RI
Oral Oncol; 2012 Dec; 48(12):1281-8. PubMed ID: 22748449
[TBL] [Abstract][Full Text] [Related]
2. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors.
Gaillard SL; Zahurak M; Sharma A; Durham JN; Reiss KA; Sartorius-Mergenthaler S; Downs M; Anders NM; Ahuja N; Rudek MA; Azad N
Cancer; 2019 Aug; 125(16):2837-2845. PubMed ID: 31012962
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma.
Niesvizky R; Ely S; Mark T; Aggarwal S; Gabrilove JL; Wright JJ; Chen-Kiang S; Sparano JA
Cancer; 2011 Jan; 117(2):336-42. PubMed ID: 20862746
[TBL] [Abstract][Full Text] [Related]
6. Romidepsin: a novel histone deacetylase inhibitor for cancer.
Bertino EM; Otterson GA
Expert Opin Investig Drugs; 2011 Aug; 20(8):1151-8. PubMed ID: 21699444
[TBL] [Abstract][Full Text] [Related]
7. A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.
Iwamoto FM; Lamborn KR; Kuhn JG; Wen PY; Yung WK; Gilbert MR; Chang SM; Lieberman FS; Prados MD; Fine HA
Neuro Oncol; 2011 May; 13(5):509-16. PubMed ID: 21377994
[TBL] [Abstract][Full Text] [Related]
8. The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis.
Robertson FM; Chu K; Boley KM; Ye Z; Liu H; Wright MC; Moraes R; Zhang X; Green TL; Barsky SH; Heise C; Cristofanilli M
J Exp Ther Oncol; 2013; 10(3):219-33. PubMed ID: 24416998
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis.
Conforti F; Davies ER; Calderwood CJ; Thatcher TH; Jones MG; Smart DE; Mahajan S; Alzetani A; Havelock T; Maher TM; Molyneaux PL; Thorley AJ; Tetley TD; Warner JA; Packham G; Ganesan A; Skipp PJ; Marshall BJ; Richeldi L; Sime PJ; O'Reilly KMA; Davies DE
Oncotarget; 2017 Jul; 8(30):48737-48754. PubMed ID: 28467787
[TBL] [Abstract][Full Text] [Related]
10. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).
Molife LR; Attard G; Fong PC; Karavasilis V; Reid AH; Patterson S; Riggs CE; Higano C; Stadler WM; McCulloch W; Dearnaley D; Parker C; de Bono JS
Ann Oncol; 2010 Jan; 21(1):109-13. PubMed ID: 19608618
[TBL] [Abstract][Full Text] [Related]
11. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.
Panicker J; Li Z; McMahon C; Sizer C; Steadman K; Piekarz R; Bates SE; Thiele CJ
Cell Cycle; 2010 May; 9(9):1830-8. PubMed ID: 20404560
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia.
Odenike OM; Alkan S; Sher D; Godwin JE; Huo D; Brandt SJ; Green M; Xie J; Zhang Y; Vesole DH; Stiff P; Wright J; Larson RA; Stock W
Clin Cancer Res; 2008 Nov; 14(21):7095-101. PubMed ID: 18981008
[TBL] [Abstract][Full Text] [Related]
13. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
Piekarz RL; Frye R; Turner M; Wright JJ; Allen SL; Kirschbaum MH; Zain J; Prince HM; Leonard JP; Geskin LJ; Reeder C; Joske D; Figg WD; Gardner ER; Steinberg SM; Jaffe ES; Stetler-Stevenson M; Lade S; Fojo AT; Bates SE
J Clin Oncol; 2009 Nov; 27(32):5410-7. PubMed ID: 19826128
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336).
Whitehead RP; Rankin C; Hoff PM; Gold PJ; Billingsley KG; Chapman RA; Wong L; Ward JH; Abbruzzese JL; Blanke CD
Invest New Drugs; 2009 Oct; 27(5):469-75. PubMed ID: 18941712
[TBL] [Abstract][Full Text] [Related]
15. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.
Grant C; Rahman F; Piekarz R; Peer C; Frye R; Robey RW; Gardner ER; Figg WD; Bates SE
Expert Rev Anticancer Ther; 2010 Jul; 10(7):997-1008. PubMed ID: 20645688
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin.
Kim SJ; Kim JH; Ki CS; Ko YH; Kim JS; Kim WS
Ann Oncol; 2016 Mar; 27(3):508-13. PubMed ID: 26658891
[TBL] [Abstract][Full Text] [Related]
17. Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy.
Pojani E; Barlocco D
Curr Med Chem; 2021; 28(7):1290-1303. PubMed ID: 32013816
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of a new schedule of romidepsin in patients with advanced cancers.
Amiri-Kordestani L; Luchenko V; Peer CJ; Ghafourian K; Reynolds J; Draper D; Frye R; Woo S; Venzon D; Wright J; Skarulis M; Figg WD; Fojo T; Bates SE; Piekarz RL
Clin Cancer Res; 2013 Aug; 19(16):4499-507. PubMed ID: 23757352
[TBL] [Abstract][Full Text] [Related]
19. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study.
Dupuis J; Morschhauser F; Ghesquières H; Tilly H; Casasnovas O; Thieblemont C; Ribrag V; Bossard C; Le Bras F; Bachy E; Hivert B; Nicolas-Virelizier E; Jardin F; Bastie JN; Amorim S; Lazarovici J; Martin A; Coiffier B
Lancet Haematol; 2015 Apr; 2(4):e160-5. PubMed ID: 26687958
[TBL] [Abstract][Full Text] [Related]
20. Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies.
Jain N; Odenike O
Expert Opin Pharmacother; 2010 Dec; 11(18):3073-84. PubMed ID: 21080855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
